heartware's loss c-pulse advantage

HeartWare backs out of a study assessing its left-ventricular assist devices in a lower-risk heart failure population, a move that analysts say won't affect the company's efforts to win FDA approval for treating higher-risk patients.


HeartWare International (NSDQ:HTWR) decided to back out of the REVIVE-IT study of its left-ventricular assist device, citing the need to focus efforts on the company's efforts to win FDA approval for the device.

The REVIVE-IT study, which the HeartWare had contributed about $600,000 to, was designed to evaluate the company's LVAD system in patients with lower-risk heart disease.